IXICO announces new contract in Huntington’s disease

IXICO today announces that it has been awarded a contract for a third clinical trial in Huntington’s disease (‘HD’) by a new US-based drug development specialty pharmaceutical customer.

The contract is for an early phase trial for a novel treatment where IXICO will be providing a battery of advanced MRI imaging techniques and clinical trial endpoints.

This follows the announcements in May and November 2014 of contracts awarded and then extended with two top 15 pharmaceutical companies. This third contract extends and consolidates IXICO’s presence in, and revenues to be derived from, this important disease area and further expands the Company’s track record and capabilities in advanced MRI imaging techniques.

By |2017-10-11T11:18:04+00:0023 April 2015|Contracts|